Nanobac Pharmaceuticals Profit Margin

Nanobac Pharmaceuticals (NNBP) currently reports a profit margin of -37319.74% as of December 2007. That compares with -2209.53% in the prior-year period — down 1589.0% year over year. That is below the Healthcare sector average of 10.58%. Use the charts on this page to explore Nanobac Pharmaceuticals's profit margin history and peer comparisons.

Nanobac Pharmaceuticals's profit margin decreased from -2209.53% to -37319.74% — a 1589.0% year-over-year decrease (period ending December 2007). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Nanobac Pharmaceuticals's profit margin of -37319.74% is lower than the Healthcare sector average of 10.58%. That is roughly 352822.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Nanobac Pharmaceuticals's current -37319.74% should be judged against Healthcare norms (sector average: 10.58%) and against NNBP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -37319.74%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 10.58%. From there, open related valuation or income-statement pages for Nanobac Pharmaceuticals, and consider following NNBP for alerts when major investors trade the stock.